InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

November 3, 2021

InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

October 13, 2021

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

September 30, 2021

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

September 24, 2021

InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar “Accelerating The Commercialization of Rare Cannabinoids”

September 17, 2021

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

September 17, 2021

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

September 13, 2021

InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th

September 7, 2021

InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

August 12, 2021

InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

July 2, 2021

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

June 29, 2021

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

June 29, 2021

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

June 17, 2021

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

June 9, 2021

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

May 13, 2021

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

May 6, 2021

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

May 4, 2021

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

April 28, 2021

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

April 27, 2021

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar “Accelerating The Commercialization of Rare Cannabinoids”

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th

InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals